Inhibrx Biosciences, Inc. $INBX Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP boosted its holdings in Inhibrx Biosciences, Inc. (NASDAQ:INBX) by 76.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 17,704 shares of the company’s stock after acquiring an additional 7,666 shares during the quarter. Quantinno Capital Management LP owned about 0.12% of Inhibrx Biosciences worth $1,190,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. PSP Research LLC purchased a new position in Inhibrx Biosciences in the 4th quarter valued at approximately $505,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Inhibrx Biosciences during the fourth quarter worth $20,856,000. SummitTX Capital L.P. boosted its position in Inhibrx Biosciences by 66.3% during the first quarter. SummitTX Capital L.P. now owns 137,821 shares of the company’s stock worth $9,266,000 after purchasing an additional 54,936 shares in the last quarter. Jefferies Financial Group Inc. acquired a new stake in Inhibrx Biosciences in the fourth quarter valued at $703,000. Finally, Vanguard Group Inc. grew its holdings in Inhibrx Biosciences by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 623,084 shares of the company’s stock valued at $49,224,000 after purchasing an additional 28,166 shares during the last quarter. Institutional investors and hedge funds own 82.46% of the company’s stock.

Inhibrx Biosciences Trading Down 8.9%

Shares of INBX opened at $88.37 on Friday. Inhibrx Biosciences, Inc. has a fifty-two week low of $22.40 and a fifty-two week high of $155.29. The company has a market capitalization of $1.30 billion, a PE ratio of -9.95 and a beta of 3.51. The stock has a fifty day moving average of $90.88 and a two-hundred day moving average of $88.48. The company has a debt-to-equity ratio of 12.58, a quick ratio of 6.46 and a current ratio of 6.46.

Inhibrx Biosciences (NASDAQ:INBX) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($2.34) EPS for the quarter, missing analysts’ consensus estimates of ($2.28) by ($0.06). As a group, analysts forecast that Inhibrx Biosciences, Inc. will post -10.15 EPS for the current year.

Analysts Set New Price Targets

INBX has been the subject of a number of research reports. Wall Street Zen upgraded shares of Inhibrx Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 9th. Lifesci Capital upgraded shares of Inhibrx Biosciences to a “strong-buy” rating in a research report on Friday, April 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibrx Biosciences in a research note on Tuesday, June 16th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $150.00.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.